Manfouz El Shahawy, MD
Cardiovascular Disease · Sarasota, FLNPI 1982646055
Payments from drug & device makers
Across 621 payments — averaging $2403.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$670K
- Novartis$277K
- Janssen Research & Development, LLC$227K
- Bayer$142K
- Merck$51K
- Novo Nordisk AS$49K
- plus $75K from 22 others
Across 1 payment — averaging $187.21 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$187
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 49 | $669,854 |
| Novartis | 18 | $277,321 |
| Janssen Research & Development, LLC | 60 | $227,125 |
| Bayer | 128 | $142,139 |
| Merck | 42 | $51,173 |
| Novo Nordisk AS | 240 | $49,309 |
| Eli Lilly | 1 | $23,643 |
| Pfizer | 8 | $16,755 |
| Sanofi US Services Inc. | 5 | $15,265 |
| Sanofi-aventis U.S. LLC | 10 | $8,114 |
| Kowa Research Institute, Inc. | 2 | $5,000 |
| Regeneron | 1 | $3,703 |
| AstraZeneca(2 entities) | 16 | $575 |
| Boehringer Ingelheim | 7 | $452 |
| Novo Nordisk | 6 | $341 |
| Johnson & Johnson | 4 | $249 |
| Actelion Pharmaceuticals US, Inc. | 2 | $246 |
| Cvrx, Inc. | 2 | $193 |
| Alnylam Pharmaceuticals Inc. | 3 | $167 |
| Janssen Scientific Affairs, LLC | 2 | $154 |
| Amarin Pharma, Inc. | 3 | $127 |
| Esperion Therapeutics, Inc. | 5 | $124 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $100 |
| Kestra Medical Technology Services, Inc. | 1 | $42 |
| Lilly USA, LLC | 2 | $38 |
| Akcea Therapeutics, Inc. | 1 | $36 |
| Regeneron Healthcare Solutions, Inc. | 1 | $24 |
| Currax Pharmaceuticals LLC | 1 | $14 |
How this compares
$1,492,284 in reported general payments places this provider in the 95th percentile of 1,740 cardiovascular disease providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other cardiovascular disease in Sarasota
- Ricardo YaryuraSarasota$1.6M
- Michael KorenGainesville$31M
- Seth BaumBoca Raton$11.1M
- Alexis GutierrezHialeah$8M
- Eric SpivackAventura$7.1M
- William OneillNaples$4.6M
- Rafik AbadierInverness$4.4M
- Alvaro MurciaPembroke Pines$4M
- David HotchkissPort Charlotte$4M
- Ferris GeorgeSt Augustine$3.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.